SHBG

Summary

SHBG (sex hormone binding globulin, HGNC:10839) is a protein-coding gene on chromosome 17p13.1, encoding Sex hormone-binding globulin (P04278). Functions as an androgen transport protein, but may also be involved in receptor mediated processes.

This gene encodes a steroid binding protein that was first described as a plasma protein secreted by the liver but is now thought to participate in the regulation of steroid responses. The encoded protein transports androgens and estrogens in the blood, binding each steroid molecule as a dimer formed from identical or nearly identical monomers. Polymorphisms in this gene have been associated with polycystic ovary syndrome and type 2 diabetes mellitus. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 6462 — RefSeq curated summary.

At a glance

• GWAS associations: 33
• Clinical variants (ClinVar): 62 total
• Druggable target: yes — 30 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001040

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10839
Approved symbol	SHBG
Name	sex hormone binding globulin
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	ABP, TEBG, MGC126834, MGC138391
Ensembl gene	ENSG00000129214
Ensembl biotype	protein_coding
OMIM	182205
Entrez	6462

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 23 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron, 1 TEC

ENST00000340624, ENST00000380450, ENST00000416273, ENST00000441599, ENST00000570353, ENST00000570527, ENST00000570547, ENST00000571153, ENST00000572182, ENST00000572262, ENST00000574539, ENST00000575314, ENST00000575618, ENST00000575729, ENST00000575903, ENST00000576152, ENST00000576478, ENST00000576728, ENST00000576747, ENST00000576830, ENST00000624152, ENST00000856862, ENST00000856863, ENST00000856864, ENST00000856865, ENST00000856866, ENST00000856867

RefSeq mRNA: 8 — MANE Select: NM_001040 NM_001040, NM_001146279, NM_001146280, NM_001146281, NM_001289113, NM_001289114, NM_001289115, NM_001289116

CCDS: CCDS11117, CCDS54082, CCDS54083, CCDS58513, CCDS73961, CCDS73962

Canonical transcript exons

ENST00000380450 — 8 exons

Exon	Start	End
ENSE00002663943	7630135	7630283
ENSE00003465540	7630680	7630869
ENSE00003485100	7633204	7633372
ENSE00003601548	7632752	7632959
ENSE00003606133	7630416	7630507
ENSE00003641466	7631879	7632015
ENSE00003648709	7631200	7631361
ENSE00003682683	7631589	7631748

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 89.19.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3340 / max 90.1901, expressed in 86 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159282	0.2147	35
159281	0.1193	49

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	89.19	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.78	gold quality
cervix squamous epithelium	UBERON:0006922	84.39	gold quality
liver	UBERON:0002107	83.79	gold quality
right testis	UBERON:0004534	78.09	gold quality
left testis	UBERON:0004533	77.20	gold quality
testis	UBERON:0000473	74.33	gold quality
hair follicle	UBERON:0002073	71.56	gold quality
right adrenal gland cortex	UBERON:0035827	71.49	gold quality
duodenum	UBERON:0002114	70.55	gold quality
adrenal tissue	UBERON:0018303	70.38	gold quality
cervix epithelium	UBERON:0004801	70.15	gold quality
right adrenal gland	UBERON:0001233	70.01	gold quality
epithelial cell of pancreas	CL:0000083	69.94	gold quality
Brodmann (1909) area 10	UBERON:0013541	68.89	gold quality
triceps brachii	UBERON:0001509	68.76	gold quality
gluteal muscle	UBERON:0002000	68.63	gold quality
squamous epithelium	UBERON:0006914	68.59	gold quality
jejunal mucosa	UBERON:0000399	68.47	gold quality
left adrenal gland	UBERON:0001234	67.91	gold quality
oocyte	CL:0000023	67.18	gold quality
adrenal cortex	UBERON:0001235	67.12	gold quality
left adrenal gland cortex	UBERON:0035825	67.07	gold quality
adult mammalian kidney	UBERON:0000082	66.57	gold quality
epithelium of esophagus	UBERON:0001976	66.43	gold quality
hindlimb stylopod muscle	UBERON:0004252	66.34	gold quality
small intestine Peyer’s patch	UBERON:0003454	66.32	gold quality
small intestine	UBERON:0002108	66.09	gold quality
esophagus squamous epithelium	UBERON:0006920	65.86	gold quality
adrenal gland	UBERON:0002369	65.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.94

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ESR1, HNF4A, HNF4G, ID1, MSC, NR3C1, NR5A1, PAX1, PPARG, SCX, TBP, USF1, USF2

Literature-anchored findings (GeneRIF, showing 40)

• A (TAAAA)(n) pentanucleotide repeat, located within an alu sequence at the 5’ boundary of the human SHBG promoter, influences its transcriptional activity in association with downstream elements, including an SP1-binding site (PMID:11473114)
• observations are consistent with the hypothesis that SHBG, destined to participate in signaling at the cell membrane, is locally regulated and produced (PMID:12015315)
• Data suggest that O-glycosylation of sex hormone-binding gllobulin is essential for SHBG binding to a membrane receptor that is responsible for inhibiting the estradiol-induced proliferation of MCF-7 breast cancer cells. (PMID:12039072)
• 2.35 A and 1.7 A crystal structures of the amino-terminal LG domain of SHBG. Resolution of a disordered region at the entrance of the human sex hormone-binding globulin steroid-binding site. (PMID:12054810)
• binds steroid ligands in specific orientations producing distinct changes in protein conformation (PMID:12065592)
• serum concentrations are elevated in kwashiorkor and anorexia nervosa but not in marasmus; marker of nutritional status in anorexia nervosa and kwashiorkor (PMID:12081841)
• polymorphisms in familial and sporadic breast cancer (PMID:12151349)
• Results describe the crystal structure of human sex hormone-binding globulin in complex with 2-methoxyestradiol. (PMID:12228253)
• Data show that human sex hormone-binding globulin (SHBG) transcripts containing an alternative exon 1 sequence are located specifically in the testicular germ cells of transgenic mice, whereas murine SHBG transcripts are confined to Sertoli cells. (PMID:12235141)
• SHBG and sex steroids showed a negative correlation with serum lipids considered a cardiovascular risk (PMID:12603009)
• study shows that for patients with polycystic ovary syndrome, sex hormone-binding globulin is an integrated marker of insulin resistance that may be of use to identify insulin-resistant individuals for targeted treatment (PMID:12679434)
• sex-hormone-binding globulin has a role in modulating tyrosinase activity at the posttranslational level through the cell membrane signaling pathway of melanocytes (PMID:12753385)
• Plasma SHBG level may represent significant predictor of metabolic syndrome in men and premenopausal women. (PMID:12800098)
• first-trimester sex hormone binding globulin levels were lower among women in whom gestational diabetes mellitus subsequently developed (PMID:12861158)
• IGFBP-1 and SHBG are equally sensitive to ambient insulin concentrations in human hepatoma cell cultures, and the production of both proteins is also attenuated by the IGFs. (PMID:14568572)
• Novel (TAAAA)n allele found in low frequency, mainly in controls. May be genetic contribution to decreased SHBG levels frequently seen in polycystic ovary syndrome(PCOS). May act as susceptibility gene, genetic link for origin. (PMID:14671199)
• May be a marker for insulin resistance in type 2 diabetes. (PMID:14694008)
• Polymorphism(s) within coding sequence and, potentially, in regulatory sequence of SHBG gene are associated with circulating SHBG levels and may represent part of genetic background of sex steroid hormone activity. (PMID:14764814)
• Low total testosterone and SHBG levels independently predict development of the metabolic syndrome and diabetes in middle-aged men. (PMID:15111517)
• SHBG androgen sensitivity test is a simple diagnostic tool for the detection of androgen receptor malfunction in gonadal dysgenesis. (PMID:15146368)
• SHBG may play a key role in male patients with idiopathic or secondary osteoporosis. (PMID:15193539)
• Serum SHBG appeared to be an independent positive predictor of bone turnover rate, which also positively associated with serum 25-hydroxyvitamin-D levels. (PMID:15292305)
• USF transcription factors repress SHBG transcription in Sertoli cells through an interaction with FP4 within its proximal promoter (PMID:15574421)
• SHBG interacts with cell membranes and causes inhibition of the anti-apoptotic effect of estradiol. (PMID:15664449)
• Estimation of genetic and nongenetic influences on endogenous sex hormones (testosterone, estradiol, estrone, and SHBG) in a large sample of 532 adult white mono- and dizygotic male twins (PMID:15755867)
• Intrahepatic cholestasis of pregnancy is associated with blunted responses of SHBG to oral estrogen. (PMID:15784702)
• Interacts with prostatic proteins in a yeast two-hybrid system. (PMID:15862967)
• TAAAA repeat polymorphism in the promoter region provides evidence for a possible association of SHBG gene with age at menarche. (PMID:15879463)
• Finds variant SHBG Asn allele (Asp327Asn) associated with reduced breast cancer risk in postmenopausal women [OR, 0.73; 95% CI (95% CI), 0.53-0.99], but not in premenopausal women [OR, 1.03; 95% CI, 0.82-1.27). (PMID:15894658)
• SHBG-immunoreactive neurons were observed in the supraoptic nucleus, the suprachiasmatic nucleus, the bed nucleus of the stria terminalis, paraventricular nucleus, arcuate nucleus, the perifornical region and the medial preoptic area in human brains. (PMID:16155373)
• Data show that some special genotypes and low serum SHBG levels may be associated with PCOS and its glucose metabolic status, but both SHBG gene polymorphism genotype and serum SHBG are not good indicators to find out the PCOS individual at high risk. (PMID:16331562)
• Low SHBG and/or androgen deficiency may provide early warning signs for cardiovascular risk and an opportunity for early intervention in nonobese men. (PMID:16394089)
• SHBG may have a role in cardiovascular disease in women with polycystic ovary syndrome (PMID:16757555)
• Polymorphisms in the SHBG promoter predict serum levels of SHBG, androgens, and glucuronidated androgen metabolites, and hip Bone Mineral Density in men. (PMID:16926255)
• A study evaluating testosterone and estradiol (E2) levels among women in relation to 5 single nucleotide polymorphisms (SNPs) of the aromatase (CYP 19) gene in women of 4 ethnic/racial groups is presented. (PMID:16949385)
• Although certain parameters of insulin status and serum SHBG demonstrated statistically significant correlation coefficients, these relationships are weak and SHBG cannot be used as a predictor of insulin resistance. (PMID:17027360)
• The present study demonstrated a time and operation effect decline in plasma DHEAS levels. In contrast, the time x operation interaction on SHBG levels exhibited an increase toward postoperative day 7. (PMID:17027364)
• SHBG, but not CYP17, CYP1B1, or COMT polymorphisms are associated with different sex hormone levels in post-menopausal breast cancer survivors (PMID:17077994)
• the (TAAAA)(n) SHBG gene polymorphism might have a role in serum SHBG expression and in hyperandrogenaemic clinical presentation of PCOS (PMID:17189294)
• D327N polymorphism of the SHBG gene does not influence susceptibility to polycystic ovary syndrome (PMID:17258903)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Shbg	ENSMUSG00000005202
rattus_norvegicus	Shbg	ENSRNOG00000011357

Paralogs (1): PROS1 (ENSG00000184500)

Protein

Protein identifiers

Sex hormone-binding globulin — P04278 (reviewed: P04278)

Alternative names: Sex steroid-binding protein, Testis-specific androgen-binding protein, Testosterone-estradiol-binding globulin, Testosterone-estrogen-binding globulin

All UniProt accessions (14): P04278, A0A0C4DGN2, B0FWH5, B0FWH6, B0FWH7, I3L0M1, I3L145, I3L1C1, I3L1G4, I3L1J1, I3L2F1, I3L2X4, I3L4B9, I3L4D0

UniProt curated annotations — full annotation on UniProt →

Function. Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.

Subunit / interactions. Homodimer.

Subcellular location. Secreted.

Tissue specificity. Isoform 1 and isoform 2 are present in liver and testis.

Post-translational modifications. Variant Asn-356 contains one N-linked (GlcNAc…) at position 356.

Isoforms (5)

UniProt ID	Names	Canonical?
P04278-1	1, SHBG, SHBGr-1	yes
P04278-2	2, Sex hormone binding globulin-gene-related protein (SHBGgrp), SHBGr-2
P04278-3	3
P04278-4	4
P04278-5	5

RefSeq proteins (8): NP_001031, NP_001139751, NP_001139752, NP_001139753, NP_001276042, NP_001276043, NP_001276044, NP_001276045 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001791	Laminin_G	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR051145	GAS-SHBG-PROS	Family

Pfam: PF00054

UniProt features (43 total): strand 16, splice variant 5, helix 5, sequence variant 4, sequence conflict 3, glycosylation site 3, domain 2, disulfide bond 2, signal peptide 1, chain 1, turn 1

Structure

Experimental structures (PDB)

13 structures.

PDB	Method	Resolution (Å)
1D2S	X-RAY DIFFRACTION	1.55
1F5F	X-RAY DIFFRACTION	1.7
1KDK	X-RAY DIFFRACTION	1.7
6PYA	X-RAY DIFFRACTION	1.71
6PYF	X-RAY DIFFRACTION	1.73
1LHW	X-RAY DIFFRACTION	1.75
6ULB	X-RAY DIFFRACTION	1.75
1LHU	X-RAY DIFFRACTION	1.8
6PYB	X-RAY DIFFRACTION	1.8
1LHN	X-RAY DIFFRACTION	2
1LHO	X-RAY DIFFRACTION	2
1LHV	X-RAY DIFFRACTION	2
1KDM	X-RAY DIFFRACTION	2.35

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P04278-F1	86.03	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 193–217, 362–390

Glycosylation sites (3): 36, 380, 396

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 70 (showing top): MODULE_16, MODULE_404, MODULE_118, MODULE_379, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, CAIRO_HEPATOBLASTOMA_DN, MODULE_88, MODULE_242, MODULE_104, MODULE_55, GOMF_STEROID_BINDING, MODULE_23, MODULE_7, GOMF_LIPID_BINDING, MODULE_181

GO Biological Process (0):

GO Molecular Function (4): steroid binding (GO:0005496), androgen binding (GO:0005497), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (2): extracellular region (GO:0005576), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
lipid binding	1
hormone binding	1
cellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

1440 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SHBG	ALB	P02768	996
SHBG	SERPINA6	P08185	952
SHBG	INS	P01308	881
SHBG	IGF1	P01343	860
SHBG	PRL	P01236	822
SHBG	ADIPOQ	Q15848	817
SHBG	AMH	P03971	792
SHBG	NRXN2	Q9P2S2	791
SHBG	LEP	P41159	763
SHBG	CYP19A1	P11511	763
SHBG	SERPINA7	P05543	753
SHBG	NRXN1	Q9ULB1	740
SHBG	ESR2	Q92731	732
SHBG	GNRH1	P01148	720
SHBG	CRP	P02741	719

IntAct

6 interactions, top by confidence:

A	B	Type	Score
TMEM236	SHBG	psi-mi:“MI:0915”(physical association)	0.400
	Trappc8	psi-mi:“MI:0915”(physical association)	0.400
		psi-mi:“MI:0914”(association)	0.350
GRB2	SHBG	psi-mi:“MI:0915”(physical association)	0.000
CLEC4G	SHBG	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (62): SHBG (Affinity Capture-MS), CNTNAP3B (Affinity Capture-MS), GNB2 (Affinity Capture-MS), SHBG (Affinity Capture-MS), SHBG (Negative Genetic), SHBG (Negative Genetic), SHBG (Proximity Label-MS), SHBG (Two-hybrid), SHBG (Two-hybrid), ASB16-AS1 (Two-hybrid), FYTTD1 (Two-hybrid), HYI (Two-hybrid), RMND5B (Two-hybrid), CECR5 (Two-hybrid), AKR1B1 (Two-hybrid)

ESM2 similar proteins: A0A140LHF2, A0EQL2, D3YZF7, D7PDD4, O15533, O55237, O70394, O70540, O95866, P04278, P05111, P07994, P08689, P0C6B3, P0DP72, P15196, P17490, P18627, P40238, P55101, P60882, P97497, Q00657, Q08351, Q14393, Q14773, Q16671, Q3SWY4, Q5BK54, Q5NKT8, Q5TJE4, Q61790, Q61826, Q62588, Q6PZD2, Q6UVK1, Q6UWB1, Q7Z7M0, Q7Z7M1, Q86VR7

Diamond homologs: A0EQL2, P04278, P08689, P15196, P97497, Q0V8T5, Q0V8T8, Q62588, Q8WYK1, Q96NU0, Q99P47, D0PRN3, O54991, P33450, P78357, Q0V8T7, Q3KN41, Q9BZ76, Q9C0A0, Q0V8T0, Q61001

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	9
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

1753 predictions. Top by Δscore:

Variant	Effect	Δscore
17:7626611:CCAC:C	acceptor_gain	1.0000
17:7626612:CAC:C	acceptor_gain	1.0000
17:7626612:CACC:C	acceptor_gain	1.0000
17:7626613:ACC:A	acceptor_loss	1.0000
17:7626615:C:CC	acceptor_gain	1.0000
17:7626615:CT:C	acceptor_loss	1.0000
17:7626616:T:G	acceptor_loss	1.0000
17:7626928:G:C	donor_gain	1.0000
17:7626990:C:A	donor_gain	1.0000
17:7627242:T:TC	acceptor_gain	1.0000
17:7627244:G:GC	acceptor_gain	1.0000
17:7627248:C:CT	acceptor_gain	1.0000
17:7627604:T:TA	donor_gain	1.0000
17:7630252:G:T	donor_gain	1.0000
17:7630508:G:GG	donor_gain	1.0000
17:7630866:CCAG:C	donor_loss	1.0000
17:7630869:GG:G	donor_loss	1.0000
17:7631195:TGCA:T	acceptor_loss	1.0000
17:7631198:A:AG	acceptor_gain	1.0000
17:7631198:AGGT:A	acceptor_gain	1.0000
17:7631199:G:GG	acceptor_gain	1.0000
17:7631199:GGT:G	acceptor_gain	1.0000
17:7631199:GGTG:G	acceptor_gain	1.0000
17:7614448:TCAC:T	donor_loss	0.9900
17:7614449:CACCT:C	donor_loss	0.9900
17:7614450:ACC:A	donor_loss	0.9900
17:7626610:GCCAC:G	acceptor_gain	0.9900
17:7626611:CCACC:C	acceptor_gain	0.9900
17:7626613:AC:A	acceptor_gain	0.9900
17:7626614:CC:C	acceptor_gain	0.9900

AlphaMissense

2577 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:7630863:G:C	W129C	0.986
17:7630863:G:T	W129C	0.986
17:7630861:T:A	W129R	0.976
17:7630861:T:C	W129R	0.976
17:7630693:T:C	F73L	0.966
17:7630695:T:A	F73L	0.966
17:7630695:T:G	F73L	0.966
17:7631630:G:C	W199C	0.961
17:7631630:G:T	W199C	0.961
17:7630763:T:C	F96S	0.959
17:7631736:T:C	F235L	0.959
17:7631738:C:A	F235L	0.959
17:7631738:C:G	F235L	0.959
17:7630762:T:C	F96L	0.956
17:7630764:T:A	F96L	0.956
17:7630764:T:G	F96L	0.956
17:7630775:T:C	L100P	0.952
17:7630720:G:A	G82R	0.947
17:7630720:G:C	G82R	0.947
17:7630864:C:G	H130D	0.944
17:7631628:T:A	W199R	0.943
17:7631628:T:C	W199R	0.943
17:7630778:G:C	R101P	0.934
17:7630703:G:C	R76P	0.933
17:7630784:G:T	G103V	0.931
17:7631737:T:C	F235S	0.930
17:7630802:T:C	L109P	0.928
17:7630823:T:C	L116P	0.928
17:7632919:G:C	W340C	0.926
17:7632919:G:T	W340C	0.926

dbSNP variants (sampled 300 via entrez): RS1000223321 (17:7633722 C>G), RS1000274522 (17:7620869 G>A), RS1000367065 (17:7629760 T>C), RS1000959745 (17:7632280 A>T), RS1000978984 (17:7614497 C>A,G,T), RS1001096819 (17:7614285 G>A,C), RS1001098626 (17:7621258 A>C), RS1001483022 (17:7628374 C>T), RS1001755466 (17:7615838 A>G), RS1001823863 (17:7616962 T>C), RS1001984611 (17:7615514 G>A), RS1002100618 (17:7615436 T>A,G), RS1002107677 (17:7617433 T>A), RS1002214784 (17:7622758 G>A,T), RS1002236681 (17:7632986 T>A,C,G)

Disease associations

OMIM: gene MIM:182205 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

33 associations (top):

Study	Trait	p-value
GCST000189_33	Protein quantitative trait loci	3.000000e-07
GCST001264_1	Testosterone levels	1.000000e-41
GCST001264_2	Testosterone levels	2.000000e-22
GCST001554_1	Sex hormone-binding globulin levels	2.000000e-16
GCST001612_12	Sex hormone-binding globulin levels	2.000000e-106
GCST001612_24	Sex hormone-binding globulin levels	2.000000e-55
GCST001612_25	Sex hormone-binding globulin levels	3.000000e-46
GCST001612_26	Sex hormone-binding globulin levels	1.000000e-24
GCST001612_27	Sex hormone-binding globulin levels	2.000000e-21
GCST001612_28	Sex hormone-binding globulin levels	1.000000e-07
GCST001612_8	Sex hormone-binding globulin levels	4.000000e-80
GCST001612_9	Sex hormone-binding globulin levels	6.000000e-30
GCST001653_1	Androgen levels	6.000000e-08
GCST001653_3	Androgen levels	1.000000e-12
GCST001653_5	Androgen levels	1.000000e-11
GCST001653_6	Androgen levels	9.000000e-10
GCST002195_6	Hormone measurements	1.000000e-08
GCST002195_7	Hormone measurements	5.000000e-19
GCST002925_8	Sex hormone levels	1.000000e-15
GCST004621_186	Red cell distribution width	7.000000e-09
GCST006979_802	Heel bone mineral density	1.000000e-14
GCST007929_53	Medication use (calcium channel blockers)	5.000000e-09
GCST009158_28	Uterine fibroids	7.000000e-31
GCST010002_119	Refractive error	3.000000e-22
GCST010703_158	Brain morphology (MOSTest)	3.000000e-09
GCST010989_19	Body size at age 10	4.000000e-09
GCST90020024_510	A body shape index	2.000000e-10
GCST90020025_1299	Waist-to-hip ratio adjusted for BMI	3.000000e-10
GCST90020025_1300	Waist-to-hip ratio adjusted for BMI	1.000000e-15
GCST90020027_546	Waist-hip index	2.000000e-11

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0004696	sex hormone-binding globulin measurement
EFO:0004908	testosterone measurement
EFO:0004909	dihydrotestosterone measurement
EFO:0004730	hormone measurement
EFO:0009188	Red cell distribution width
EFO:0009270	heel bone mineral density
EFO:0009930	Calcium channel blocker use measurement
EFO:0004346	neuroimaging measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0004697	estradiol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3305 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

30 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538,597 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL103	PROGESTERONE	4	162,141
CHEMBL1162	NORETHINDRONE	4	91,150
CHEMBL135	ESTRADIOL	4	123,080
CHEMBL1395	METHYLTESTOSTERONE	4	486,600
CHEMBL1405	ESTRONE	4	36,722
CHEMBL1479	DANAZOL	4	16,256
CHEMBL1531	ETONOGESTREL	4	4,893
CHEMBL1533	DESOGESTREL	4	9,566
CHEMBL193482	ESTRIOL	4	21,295
CHEMBL2107797	NORGESTREL	4	10,747
CHEMBL258918	MESTEROLONE	4	2,485
CHEMBL386630	TESTOSTERONE	4	129,997
CHEMBL389621	HYDROCORTISONE	4	207,645
CHEMBL691	ETHINYL ESTRADIOL	4	40,543
CHEMBL717	MEDROXYPROGESTERONE ACETATE	4	51,452
CHEMBL90593	PRASTERONE	4	23,422
CHEMBL110739	CORTICOSTERONE	3	28,274
CHEMBL1499	CORTISONE	3	79,011
CHEMBL241694	ETHISTERONE	3	3,833
CHEMBL757	NANDROLONE	3	9,485
CHEMBL1868702	GESTRINONE	2
CHEMBL253144	CORTODOXONE	2
CHEMBL259548	BOLASTERONE	2
CHEMBL261514	MESTANOLONE	2
CHEMBL273453	ALDOSTERONE	2
CHEMBL27769	STANOLONE	2
CHEMBL282575	ESTRADIOL BENZOATE	2
CHEMBL299613	2-METHOXYESTRADIOL	2
CHEMBL44	GENISTEIN	2
CHEMBL253363	PREGNENOLONE	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
4-((1S,2S,5S,6S,9R)-5-Hydroxymethyl-6,8,9-trimethyl-3-oxa-bicyclo[3.3.1]non-7-en-2-yl)-2-methoxy-phenol	IC50	22400 nM

ChEMBL bioactivities

93 potent at pChembl≥5 of 103 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.74	Kd	0.182	nM	STANOLONE
9.74	Kd	0.182	nM	CHEMBL260202
9.60	Kd	0.2512	nM	MESTEROLONE
9.54	Kd	0.2884	nM	CHEMBL259126
9.38	Kd	0.4169	nM	CHEMBL411053
9.32	Kd	0.4786	nM	CHEMBL265926
9.31	Kd	0.4898	nM	CHEMBL265925
9.20	Kd	0.631	nM	TESTOSTERONE
9.17	Kd	0.6761	nM	ANDROSTENEDIOL
9.12	Kd	0.7586	nM	CHEMBL260660
9.11	Kd	0.7762	nM	ANDROSTANDIOL
9.08	Kd	0.8318	nM	2-METHOXYESTRADIOL
9.07	Kd	0.8511	nM	CHEMBL260659
9.05	Kd	0.8913	nM	CHEMBL261866
9.05	Kd	0.8913	nM	CHEMBL408707
9.00	Kd	1	nM	CHEMBL195836
9.00	Kd	1	nM	CHEMBL261643
8.91	Kd	1.23	nM	NORGESTREL
8.91	Kd	1.23	nM	CHEMBL410519
8.83	Kd	1.479	nM	ESTRADIOL
8.81	Kd	1.549	nM	MESTANOLONE
8.80	Kd	1.585	nM	CHEMBL408973
8.78	Kd	1.66	nM	ETHISTERONE
8.76	Kd	1.738	nM	CHEMBL223967
8.76	Kd	1.738	nM	BOLASTERONE
8.71	Kd	1.95	nM	CHEMBL359619
8.62	Kd	2.399	nM	CHEMBL121458
8.62	Kd	2.399	nM	EQUILENIN
8.57	Kd	2.692	nM	CHEMBL265942
8.51	Kd	3.09	nM	EQUILIN
8.51	Kd	3.09	nM	CHEMBL259599
8.46	Kd	3.467	nM	CHEMBL411731
8.46	Kd	3.467	nM	CHEMBL430043
8.43	Kd	3.715	nM	METHYLTESTOSTERONE
8.42	IC50	3.8	nM	STANOLONE
8.36	Kd	4.365	nM	CHEMBL409895
8.36	Kd	4.365	nM	CHEMBL260639
8.36	Kd	4.365	nM	CHEMBL260641
8.36	Kd	4.365	nM	CHEMBL260640
8.36	Kd	4.365	nM	CHEMBL411730
8.30	Kd	5.012	nM	CHEMBL261406
8.27	Kd	5.37	nM	CHEMBL261407
8.23	Kd	5.888	nM	ETONOGESTREL
8.23	Kd	5.888	nM	CHEMBL406406
8.20	Kd	6.31	nM	DANAZOL
8.18	Kd	6.607	nM	ESTRONE
8.11	Kd	7.762	nM	GESTRINONE
7.97	Kd	10.72	nM	NORETHINDRONE
7.92	Kd	12.02	nM	CHEMBL411316
7.88	Kd	13.18	nM	CHEMBL409084

PubChem BioAssay actives

93 with measured affinity, of 320 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0002	uM
(5S,8R,9S,10S,13S,14S,17R)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0002	uM
(1S,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-1,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0003	uM
(3S,8R,9S,10R,13S,14S,17S)-13-methyl-1,2,3,4,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0003	uM
(5S,7R,8R,9S,10S,13S,14S,17S)-17-hydroxy-7,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0004	uM
(8R,9S,10R,13S,14S,17S)-17-hydroxy-4,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0005	uM
(8R,9S,13S,14S,17S)-2-iodo-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0005	uM
Testosterone	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0006	uM
(3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0007	uM
(3R,5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0008	uM
(13S,14S,17S)-13-methyl-11,12,14,15,16,17-hexahydrocyclopenta[a]phenanthrene-2,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0008	uM
(8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0008	uM
(5S,7R,8R,9S,10S,13S,14S,17S)-17-hydroxy-7,10,13,17-tetramethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0009	uM
(7R,8R,9R,10R,13S,17S)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0009	uM
(5S,6S,8R,9S,10R,13S,14S,17S)-6-fluoro-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0009	uM
(3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0010	uM
(3S,5S,7R,8R,9S,10S,13S,14S,17S)-7,10,13-trimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0010	uM
(3S,8R,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0012	uM
(8R,9S,10R,13S,14S)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0012	uM
(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0015	uM
Estradiol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0015	uM
(5S,8S,9R,10S,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,4,5,6,7,8,9,10,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0016	uM
(7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,10,13,17-tetramethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0017	uM
(8R,9S,13S,14S,17S)-13-methyl-8,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0017	uM
(8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0017	uM
(7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0019	uM
(9S,13S,14S,17S)-13-methyl-6,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0024	uM
(13S,14S)-3-hydroxy-13-methyl-12,14,15,16-tetrahydro-11H-cyclopenta[a]phenanthren-17-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0024	uM
(7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,10,13,17-tetramethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0027	uM
(9S,13S,14S)-3-hydroxy-13-methyl-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0031	uM
(7R,8S,9R,10S,13S,14S,17S)-9-fluoro-17-hydroxy-7,10,13-trimethyl-2,6,7,8,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0031	uM
(7R,8R,9R,10S,13S,14S,17S)-17-hydroxy-7,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0035	uM
(3S,5S,7R,8R,9S,10S,13S,14S,17S)-7,10,13,17-tetramethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0035	uM
Methyltestosterone	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0037	uM
(7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0044	uM
(8R,9R,10S,13S,14S,17S)-17-hydroxy-13-methyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0044	uM
(8R,9S,10R,13S,14S)-10,13,17-trimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0044	uM
(6S,8R,9S,10R,13S,14S,17S)-17-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0044	uM
(5S,8R,9S,10S,13S,14S,17R)-17-ethynyl-3,3-difluoro-10,13-dimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0044	uM
(8S,9S,13S,14S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0050	uM
(3R,5S,7R,8S,9R,10S,13S,14S,17R)-13-ethyl-17-ethynyl-7-methyl-11-methylidene-1,2,3,4,5,6,7,8,9,10,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0054	uM
(8S,9R,10S,13S,14S,17S)-9-fluoro-17-hydroxy-10,13,17-trimethyl-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthrene-3,11-dione	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0059	uM
Etonogestrel	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0059	uM
Danazol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0063	uM
Estrone	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0066	uM
(8S,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0078	uM
Norethindrone	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0107	uM
(8R,9S,10R,13S,14S,16R,17R)-16,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0120	uM
(3S,8S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-10-methyl-11-methylidene-2,3,6,7,8,9,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-diol	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0132	uM
prasterone	318680: Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	kd	0.0144	uM

CTD chemical–gene interactions

124 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Ethinyl Estradiol	affects binding, affects cotreatment, increases expression	9
bisphenol A	affects response to substance, increases secretion, affects binding, decreases expression, decreases secretion	5
Estradiol	increases expression, increases reaction, affects binding, affects expression	5
Tamoxifen	affects binding, increases expression	4
Benzo(a)pyrene	decreases expression, decreases methylation, increases expression	3
Testosterone	affects binding, increases expression	3
Aflatoxin B1	decreases expression, decreases methylation, increases expression	3
Levonorgestrel	affects binding, affects cotreatment, increases expression	3
propylparaben	affects binding, decreases secretion	2
methylparaben	affects binding, decreases secretion	2
o,p’-DDT	affects binding, decreases reaction	2
norgestimate	affects cotreatment, increases expression	2
sodium arsenite	increases expression	2
mono-benzyl phthalate	increases secretion, decreases secretion, increases abundance, increases expression	2
Dibutyl Phthalate	affects binding, increases abundance, increases expression, increases secretion	2
Mitotane	increases expression, increases reaction, affects binding	2
Quercetin	affects binding, increases expression	2
Dihydrotestosterone	affects binding, decreases reaction	2
Toremifene	affects binding, increases expression	2
Genistein	affects binding, increases expression	2
Raloxifene Hydrochloride	increases expression	2
aristolochic acid I	increases expression	1
2-hydroxyestradiol	increases expression	1
3-deoxyestrone	affects binding	1
2,4,6-tribromophenol	increases expression	1
dioxybenzone	affects binding	1
naringenin	affects binding	1
diethyl phthalate	affects binding	1
tetramethrin	affects binding	1
triclocarban	decreases secretion	1

ChEMBL screening assays

34 unique, capped per target: 26 binding, 7 admet, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1025919	Binding	Binding affinity to SHBG	Lignans interfering with 5 alpha-dihydrotestosterone binding to human sex hormone-binding globulin. — J Nat Prod
CHEMBL1037223	ADMET	Binding affinity to human sex hormone binding globulin after 30 mins by size-exclusion HPLC analysis	Radiolabeled 5-iodo-3’-O-(17beta-succinyl-5alpha-androstan-3-one)-2’-deoxyuridine and its 5’-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation. — J Med Chem
CHEMBL847537	Functional	Inhibition of hSHBG (human sex hormone binding globulin )	A novel, nonsteroidal inhibitor of androgen binding to the rat androgen binding protein: diethyl [[[3-(2,6-dimethyl-4-pyridinyl)-4-fluorophenyl]amino]methylene] propanedioate. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.